<DOC>
	<DOC>NCT00620035</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the use of the next generation applicator and its instructions for proper insertion of the Radiopaque Implant. Secondary objectives include: evaluation of implant removal, evaluation of the overall contraceptive efficacy and safety of the Radiopaque Implant, assessment of x -ray visibility of the Radiopaque Implant, and to assess participant expectations and satisfaction with the Radiopaque Implant.</brief_summary>
	<brief_title>A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)</brief_title>
	<detailed_description />
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<criteria>Woman of at least (&gt;=) 18 but not older than (&lt;= )40 years of age at the time of screening; Good physical and mental health; Regular cycles with a usual length between 24 and 35 days; Body mass index &gt;= 18 and &lt;= 35 kg/m^2; Willing to give informed consent in writing. Contraindications: known or suspected pregnancy; active venous thromboembolic disorder (e.g. deep vein thrombosis, pulmonary embolism); presence or history of severe hepatic disease as long as liver function values have not returned to normal; malignancy or premalignancy, if sexsteroidinfluenced; undiagnosed vaginal bleeding; hypersensitivity to any of the components of Radiopaque Implant. Hypertension, i.e. systolic blood pressure &gt;140 mmHg and/or diastolic blood pressure &gt; 90 mmHg; A history during pregnancy or during previous use of sex steroids of: jaundice and/or severe pruritus related to cholestasis, gallstone formation, porphyria, systemic lupus erythematosus, haemolytic uraemic syndrome, Sydenham's chorea, herpes gestationis, otosclerosisrelated hearing loss; Present use or use during 2 months prior to the start of Radiopaque Implant of one of the following drugs: phenytoin, phenobarbital, primidone, carbamazepine, rifampicin, oxcarbazepine, topiramate, felbamate, ritonavir, nelfinavir, griseofulvin or the herbal remedy St John's wort; Administration of investigational drugs within 2 months prior to the start of Radiopaque Implant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>